Randomized Clinical Study of Maintenance Therapy with immunomodulator MGN1703 in Patients with Extensive Disease Small Cell Lung Cancer after Platinum-Based First-Line Therapy

Trial Profile

Randomized Clinical Study of Maintenance Therapy with immunomodulator MGN1703 in Patients with Extensive Disease Small Cell Lung Cancer after Platinum-Based First-Line Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Lefitolimod (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms IMPULSE
  • Sponsors Mologen
  • Most Recent Events

    • 24 Apr 2017 According to a Mologen media release, a more extensive evaluation of the study data is currently ongoing, and the full IMPULSE study results will be presented at international scientific conferences. There will be a final read-out probably in the first quarter of 2018, approximately 24 months following the recruitment of the last patient.
    • 24 Apr 2017 Subgroup results published in a Mologen media release.
    • 22 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top